via University at Buffalo
Model could support the assessment of long-term chronic drug therapies and help clinicians develop more effective treatments for complex diseases
Using artificial intelligence, a team of University at Buffalo researchers has developed a novel system that models the progression of chronic diseases as patients age.
Published in Oct. in the Journal of Pharmacokinetics and Pharmacodynamics, the model assesses metabolic and cardiovascular biomarkers – measurable biological processes such as cholesterol levels, body mass index, glucose and blood pressure – to calculate health status and disease risks across a patient’s lifespan.
The findings are critical due to the increased risk of developing metabolic and cardiovascular diseases with aging, a process that has adverse effects on cellular, psychological and behavioral processes.
“There is an unmet need for scalable approaches that can provide guidance for pharmaceutical care across the lifespan in the presence of aging and chronic co-morbidities,” says lead author Murali Ramanathan, PhD, professor of pharmaceutical sciences in the UB School of Pharmacy and Pharmaceutical Sciences. “This knowledge gap may be potentially bridged by innovative disease progression modeling.”
The model could facilitate the assessment of long-term chronic drug therapies, and help clinicians monitor treatment responses for conditions such as diabetes, high cholesterol and high blood pressure, which become more frequent with age, says Ramanathan.
Additional investigators include first author and UB School of Pharmacy and Pharmaceutical Sciences alumnus Mason McComb, PhD; Rachael Hageman Blair, PhD, associate professor of biostatistics in the UB School of Public Health and Health Professions; and Martin Lysy, PhD, associate professor of statistics and actuarial science at the University of Waterloo.
The research examined data from three case studies within the third National Health and Nutrition Examination Survey (NHANES) that assessed the metabolic and cardiovascular biomarkers of nearly 40,000 people in the United States.
Biomarkers, which also include measurements such as temperature, body weight and height, are used to diagnose, treat and monitor overall health and numerous diseases.
The researchers examined seven metabolic biomarkers: body mass index, waist-to-hip ratio, total cholesterol, high-density lipoprotein cholesterol, triglycerides, glucose and glycohemoglobin. The cardiovascular biomarkers examined include systolic and diastolic blood pressure, pulse rate and homocysteine.
By analyzing changes in metabolic and cardiovascular biomarkers, the model “learns” how aging affects these measurements. With machine learning, the system uses a memory of previous biomarker levels to predict future measurements, which ultimately reveal how metabolic and cardiovascular diseases progress over time.
Original Article: AI-powered computer model predicts disease progression during aging
More from: University at Buffalo | University of Waterloo
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Long-term chronic drug therapies
- Probe into Avastin use: Infected patients at long-term risk of blindness, warn experts
Experts say the bacterium leaves a drastic impact on people's vision as it appears chronic, rather than being acute, in most cases.
- Experimental treatment pushed by ALS patients gets day before FDA, but agency unconvinced it works
The Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig's disease.
- FDA skeptical of experimental ALS treatment pushed by patient advocates
The Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease ...
- Long Term (>30 Days) Residential Treatment Centers in Phoenix, AZ
Vogue Recovery Center has residential treatment ... and drug addict get sober and stay sober for life. We help identify and address emotional and behavioral obstacles to long-term recovery ...
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic ... cytarabine. Long-term analyses included overall survival, response to treatment, and serious ...
Go deeper with Google Headlines on:
Long-term chronic drug therapies
[google_news title=”” keyword=”long-term chronic drug therapies” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Progression of chronic diseases
- Slowing down the progression of kidney disease
Recently, I was told that I have stage 3 chronic kidney disease (CKD). I am not overweight, do not have diabetes and have no history of CKD in my family. I try to keep up my hydration level, but I ...
- US FDA approves Jardiance® for the treatment of adults with chronic kidney disease
The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage ...
- FDA Grants Approval for Empagliflozin in Chronic Kidney Disease
This approval marks the fourth endorsement by the FDA for empagliflozin, all of which have been linked to the EMPOWER program.
- Jardiance Approved for Adults With Chronic Kidney Disease
cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of progression. Patients were randomly assigned to receive empagliflozin 10mg or placebo once daily, in ...
- Eli Lilly: FDA Approves Jardiance In Treatment Of Chronic Kidney Disease
Boehringer Ingelheim and Eli Lilly and Company (LLY) announced the FDA has approved Jardiance 10 mg tablets to reduce the risk of ...
Go deeper with Google Headlines on:
Progression of chronic diseases
[google_news title=”” keyword=”progression of chronic diseases” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
